J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment
  
Johnson_and_Johnson
The FDA approved J&J's Darzalex for high-risk smoldering myeloma.

More from Anticancer

More from Therapy Areas